AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21397720 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF receptor expression
Number of subjects: 0
Study 18286870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (long-term use)
Number of subjects: 99
Study 18286870 — intervention group
Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HIV control group)
Number of subjects: 99
Study 16545330 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (150 microg Nestorone and 15 microg ethinyl estradiol)
Number of subjects: 45
Study 16545330 — intervention group
Group type: COMPARATOR
Intervention: Stediril 30 (oral contraceptive containing levonorgestrel)
Number of subjects: 45
Study 12677155 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 279
Study 12677155 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 279
Study 11261274 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 0
Study 11261274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose consolidation therapy
Number of subjects: 0
Study 11261274 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 0
Study 9171464 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercise during decompression
Number of subjects: 29
Study 9171464 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise during decompression
Number of subjects: 29
Study 9171464 — intervention group
Group type: COMPARATOR
Intervention: Inactive controls
Number of subjects: 29
Study 1608898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile delivery system for captopril
Number of subjects: 8
Study 6282024 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (200 mg)
Number of subjects: 8
Study 6282024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30315394 — intervention group
Group type: EXPERIMENTAL
Intervention: iRBD patients
Number of subjects: 10
Study 30315394 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 29394175 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 10)
Number of subjects: 42
Study 29394175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1‐Hz) stimulation of the nonaffected hemisphere (n = 11)
Number of subjects: 42
Study 29394175 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (10‐Hz) stimulation of the affected hemisphere (n = 13)
Number of subjects: 42
Study 29394175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of low‐ and high‐frequency stimulations (n = 8)
Number of subjects: 42
Study 27032884 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection after ESD
Number of subjects: 67
Study 27032884 — intervention group
Group type: COMPARATOR
Intervention: Control group (ESD only)
Number of subjects: 67
Study 24395980 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker treatment
Number of subjects: 3019
Study 24395980 — intervention group
Group type: COMPARATOR
Intervention: Not treated with β-blockers
Number of subjects: 3019
Study 21383686 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront therapy for aGVHD
Number of subjects: 83
Study 21383686 — intervention group
Group type: COMPARATOR
Intervention: No response to therapy by day 28
Number of subjects: 83
Study 19444142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 396
Study 19444142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 396
Study 19444142 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 396
Study 19444142 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 396
Study 19444142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren-based therapy
Number of subjects: 396
Study 17464949 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide (12 g/m(2)/cycle)
Number of subjects: 22
Study 17464949 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ifosfamide (6 g/m(2)/cycle)
Number of subjects: 22
Study 17464949 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (ERMBT)
Number of subjects: 22
Study 17130195 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based glucose monitoring system (IBGMS)
Number of subjects: 80
Study 17130195 — intervention group
Group type: COMPARATOR
Intervention: Conventional office visits
Number of subjects: 80
Study 12762613 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sandwich restoration using resin modified glass ionomer (Fuji II LCor Photac‐Fil) and microhybrid flowable composite (Aeliteflo or Flow‐it)
Number of subjects: 0
Study 12762613 — intervention group
Group type: COMPARATOR
Intervention: Conventional amalgam (Tytin) restorations
Number of subjects: 0
Study 10786226 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary beta-hexosaminidase determinations in patients on methadone substitution
Number of subjects: 0
Study 8730122 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma 0.01 mg/m2/day for 1 week, followed by 0.1 mg/m2/day intramuscularly for 18 weeks
Number of subjects: 20
Study 8730122 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 20
Study 1831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 7091876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally)
Number of subjects: 12
Study 7091876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29986717 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP)
Number of subjects: 3151
Study 29986717 — intervention group
Group type: COMPARATOR
Intervention: Rapid diagnostic tests (RDTs)
Number of subjects: 3151
Study 29986717 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP on collected RDTs
Number of subjects: 3151
Study 25545309 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 74
Study 25545309 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 74
Study 25545309 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 74
Study 23138883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 39
Study 23138883 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 39
Study 21239519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (10 mg) with GH (0.6 mg/d)
Number of subjects: 11
Study 21239519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone (40 mg) with GH (0.6 mg/d)
Number of subjects: 11
Study 21239519 — intervention group
Group type: COMPARATOR
Intervention: GH therapy alone
Number of subjects: 11
Study 21239519 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone (10 mg)
Number of subjects: 11
Study 21239519 — intervention group
Group type: COMPARATOR
Intervention: Oral testosterone (40 mg)
Number of subjects: 11
Study 18268144 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI + OMT
Number of subjects: 314
Study 18268144 — intervention group
Group type: COMPARATOR
Intervention: OMT
Number of subjects: 314
Study 18268144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemia reduction
Number of subjects: 314
Study 18268144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with moderate to severe baseline ischemia
Number of subjects: 314
Study 18268144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no residual ischemia
Number of subjects: 314
Study 16344520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 16344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset 1 predictors (age at disease onset, disease duration, sex, EDSS at baseline, number of relapses in the last 24 months, disease course)
Number of subjects: 821
Study 16344520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset 2 predictors (Subset 1 plus gadolinium enhancement status)
Number of subjects: 821
Study 12528101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg plus MTX
Number of subjects: 271
Study 12528101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg plus MTX
Number of subjects: 271
Study 12528101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg plus MTX
Number of subjects: 271
Study 12528101 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 271
Study 10816895 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg)
Number of subjects: 28
Study 10816895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, 16 million U1 intramuscularly daily for 2 weeks, then three times a week
Number of subjects: 136
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, 24 weeks treatment
Number of subjects: 136
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, 40 weeks treatment
Number of subjects: 136
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, long-term treatment
Number of subjects: 136
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, treatment for HCV-RNA genotype 1b and 2a or 2b
Number of subjects: 136
Study 8899499 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, 40 weeks treatment for patients with mild liver tissue damage or low virus counts
Number of subjects: 136
Study 2056598 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 ml 2% lidocaine jelly
Number of subjects: 241
Study 2056598 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 2% lidocaine jelly
Number of subjects: 241
Study 6409634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (22% of energy as total fat, 4% as polyunsaturated fatty acids)
Number of subjects: 95
Study 6409634 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat diet (30% of energy as total fat; 11% as polyunsaturated fatty acids)
Number of subjects: 95
Study 31653228 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 524
Study 31653228 — intervention group
Group type: COMPARATOR
Intervention: Consultation liaison
Number of subjects: 524
Study 27864694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks for the first 6 of 8 cycles and for 10 doses postoperatively)
Number of subjects: 1206
Study 27864694 — intervention group
Group type: COMPARATOR
Intervention: Control (no bevacizumab)
Number of subjects: 1206
Study 26016168 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming (group A, n = 21)
Number of subjects: 43
Study 26016168 — intervention group
Group type: COMPARATOR
Intervention: No prewarming (group B, n = 22)
Number of subjects: 43
Study 26016168 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI below 25
Number of subjects: 43
Study 26016168 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI above 25
Number of subjects: 43
Study 24903511 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin reload
Number of subjects: 500
Study 24903511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 22533496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime dose of ARB
Number of subjects: 109
Study 22533496 — intervention group
Group type: COMPARATOR
Intervention: Morning dose of ARB
Number of subjects: 109
Study 18708615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/d
Number of subjects: 685
Study 18708615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 17575470 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐week treadmill exercise program (target lactate 2.5 +/‐ 0.5 mmol/l)
Number of subjects: 54
Study 17575470 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 54
Study 15220227 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin aspart
Number of subjects: 32
Study 15220227 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with once-daily glargine and premeal/snack insulin aspart
Number of subjects: 32
Study 11353429 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric needle electrode (CNE) (diameter = 0.46 mm)
Number of subjects: 90
Study 11353429 — intervention group
Group type: COMPARATOR
Intervention: Monopolar needle electrode (MNE) (diameter = 0.41 mm)
Number of subjects: 90
Study 9142019 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (n = 179)
Number of subjects: 357
Study 9142019 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning (n = 178)
Number of subjects: 357
Study 9142019 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 357
Study 9142019 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 357
Study 7911266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofilan (SPG)
Number of subjects: 15
Study 7911266 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 3316061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide
Number of subjects: 24
Study 3316061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29435758 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality Training (12 hours of training on Virtual Reality and box trainer)
Number of subjects: 64
Study 29435758 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 64
Study 29435758 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality Training
Number of subjects: 64
Study 29435758 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 29435758 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior residents (Training)
Number of subjects: 64
Study 29435758 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior residents
Number of subjects: 64
Study 26358375 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis
Number of subjects: 46
Study 26358375 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 46
Study 25219946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayushman-15A
Number of subjects: 81
Study 25219946 — intervention group
Group type: COMPARATOR
Intervention: Ayushman-15B
Number of subjects: 81
Study 25219946 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 81
Study 23699508 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prefrontal inhibitory regulation in short-allele (s) carriers
Number of subjects: 0
Study 23699508 — intervention group
Group type: COMPARATOR
Intervention: Homozygous long-allele carriers
Number of subjects: 0
Study 21169170 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week therapist-assisted Web-based treatment
Number of subjects: 106
Study 21169170 — intervention group
Group type: COMPARATOR
Intervention: 8-week attention-placebo intervention
Number of subjects: 106
Study 17711615 — intervention group
Group type: EXPERIMENTAL
Intervention: Case formulation (CF) in cognitive behaviour therapy
Number of subjects: 13
Study 16802254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cardiorespiratory and resistance exercise training program (8-week, 3 sessions per week, 90 minutes each)
Number of subjects: 16
Study 16802254 — intervention group
Group type: COMPARATOR
Intervention: Control non-exercising group
Number of subjects: 16
Study 14616330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (O4)
Number of subjects: 90
Study 14616330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg IV (O8)
Number of subjects: 90
Study 14616330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) (P)
Number of subjects: 90
Study 10819278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (500,000 KIU)
Number of subjects: 301
Study 10819278 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose aprotinin (1,000,000 KIU load, 250,000 KIU/hr infusion)
Number of subjects: 301
Study 10819278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2,000,000 KIU load, 500,000 KIU/hr infusion)
Number of subjects: 301
Study 10819278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (all doses combined)
Number of subjects: 301
Study 10819278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9092709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegic solution
Number of subjects: 35
Study 9092709 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegic solution
Number of subjects: 35
Study 8442967 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg diluted in 10 ml saline)
Number of subjects: 16
Study 8442967 — intervention group
Group type: COMPARATOR
Intervention: Epidural lidocaine (10 ml of 2% lidocaine)
Number of subjects: 16
Study 3522818 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 50
Study 3522818 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CLP)
Number of subjects: 50
Study 31862447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedure for treatment of intermittent exotropia in children aged 3 to <5 years.
Number of subjects: 197
Study 31862447 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedure for treatment of intermittent exotropia in children aged 5 to <11 years.
Number of subjects: 197
Study 31509993 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Animal Interaction with therapy dogs only (100% HAI)
Number of subjects: 0
Study 31509993 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal combinations of Academic Stress Management and HAI (50% HAI)
Number of subjects: 0
Study 31509993 — intervention group
Group type: COMPARATOR
Intervention: Evidence‐based Academic Stress Management content only (0% HAI)
Number of subjects: 0
Study 27339738 — intervention group
Group type: EXPERIMENTAL
Intervention: obinutuzumab or rituximab induction therapy (IT) for 4 weeks
Number of subjects: 75
Study 27339738 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive after IT
Number of subjects: 75
Study 27339738 — intervention group
Group type: EXPERIMENTAL
Intervention: PET assessment using Deauville five-point scale criteria
Number of subjects: 75
Study 27339738 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in standardized uptake value and other PET parameters
Number of subjects: 75
Study 25547339 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Number of subjects: 238
Study 25547339 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238
Study 25547339 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 238
Study 23797811 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Number of subjects: 132
Study 23797811 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 132
Study 19736173 — intervention group
Group type: EXPERIMENTAL
Intervention: MyWellness Key accelerometer
Number of subjects: 16
Study 19444558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol group (F-P group)
Number of subjects: 59
Study 19444558 — intervention group
Group type: COMPARATOR
Intervention: Saline-propofol group (S-P group)
Number of subjects: 59
Study 16713991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group KM: KT program with 6-month weight and targeted behavior's self-monitoring
Number of subjects: 205
Study 16713991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group K: KT program only
Number of subjects: 205
Study 16713991 — intervention group
Group type: COMPARATOR
Intervention: Group BM: untailored self-help booklet with 7-month self-monitoring of weight and walking
Number of subjects: 205
Study 16713991 — intervention group
Group type: COMPARATOR
Intervention: Group B: self-help booklet only
Number of subjects: 205
Study 15121645 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy
Number of subjects: 50
Study 15121645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 50
Study 11421838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of the spinal region prior to epidural puncture
Number of subjects: 72
Study 11421838 — intervention group
Group type: COMPARATOR
Intervention: Standard loss of resistance technique (control group)
Number of subjects: 72
Study 9508174 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. methotrexate (MTX) and cranial radiation therapy (CRT) (regimen A, n = 317)
Number of subjects: 636
Study 9508174 — intervention group
Group type: EXPERIMENTAL
Intervention: intensified i.t. methotrexate alone (regimen B, n = 319)
Number of subjects: 636
Study 9508174 — intervention group
Group type: COMPARATOR
Intervention: Comparison of regimen A and regimen B
Number of subjects: 636
Study 9419751 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA infusion (1 mg/hour for 17 hours)
Number of subjects: 5
Study 3354444 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 0
Study 3354444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8420868 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole combined with radiation therapy
Number of subjects: 779
Study 8420868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial treatment responders
Number of subjects: 779
Study 8420868 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with <= 3 lesions
Number of subjects: 779
Study 8420868 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with favorable clinical characteristics (age <= 60, KPS >= 70, primary lesion absent or controlled, brain as sole site of metastasis)
Number of subjects: 779
Study 321177 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (300 or 600 mg)
Number of subjects: 230
Study 321177 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg)
Number of subjects: 230